特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
580811

癌のリキッドバイオプシー (液体生検) 市場評価

Cancer Liquid Biopsy Market Assessment

出版日: | 発行: Kalorama Information | ページ情報: 英文 91 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.37円
癌のリキッドバイオプシー (液体生検) 市場評価
出版日: 2017年11月08日
発行: Kalorama Information
ページ情報: 英文 91 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の癌向けリキッドバイオプシー (液体生検) 市場について調査分析し、各種リキッドバイオプシー技術、開発における課題、競合状況と市場動向、主要企業、および癌種類別の市場概要と収益予測など、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 リキッドバイオプシー技術

  • イントロダクション
  • 現在の主なリキッドバイオプシー技術
  • 循環フリーDNA
  • リキッドバイオプシーにおけるctDNAのメリット・デメリット
  • 現在のctDNA型リキッドバイオプシー検査
  • 循環腫瘍細胞 (CTC) リキッドバイオプシー
  • CTC型リキッドバイオプシー検査の開発における課題
  • CTC型リキッドバイオプシー試験
  • 細胞外小胞およびその他のリキッドバイオプシー
  • 細胞外小胞型リキッドバイオプシー試験

第3章 リキッドバイオプシー産業の分析

  • イントロダクション
  • 競合のティア
  • 競合要因
  • 顕著な市場動向

第4章 癌のリキッドバイオプシー市場分析

  • 全体的なリキッドバイオプシー市場の概要
  • リキッドバイオプシー市場の上位10社
  • 乳癌
  • 大腸癌
  • 肺癌
  • 卵巣癌
  • 前立腺癌
  • その他の癌
目次
Product Code: KLI15527193

Cancer Liquid Biopsy Market Assessment (Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer)

The term liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

The Worldwide Market for Liquid Biopsy contains markets for the following:

  • Breast Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Colorectal Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Lung Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Ovarian Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Pancreatic Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Other Cancer Liquid Biopsy Market (by Region - US, EUR, ASIA, ROW)
  • Top Ten Companies in the Market

The currently available liquid biopsy technologies employ the analysis of various types of analytes, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, proteins, miRNA and mRNA. Among them, ctDNA and CTCs have been the most explored technologies for commercial applications up to the present time.

Circulating tumor DNA (ctDNA) encompasses the small fragments of DNA that are believed to originate from the natural and abnormal necrosis and apoptosis processes that tumor cells undergo regularly. ctDNA fragments have the advantage of being available from different types of specimens, including urine, plasma, blood, and cerebrospinal fluid, but are rare and have a short half-life in the bloodstream, which makes their isolation and identification highly challenging. Since many cancer patients shed only very small DNA fragments into the bloodstream, ctDNA-based diagnostic technologies need to be highly sensitive in order to detect such rare events. Furthermore, ctDNA cannot provide information about protein expression, and the analysis of RNA is also difficult and limited using ctDNA. ctDNA may also result from tumor cells killed by therapeutic drugs, and does not capture information about the residual cancer that may not respond to the particular therapy or has become resistant to it.

Circulating tumor cells (CTCs) are cancer cells that are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs, initiating the process of metastasis, and forming new tumors. Similarly to ctDNA, CTC-based tests could offer significant advantages compared to tissue biopsies, as they may be able to capture the heterogeneity of tumors and their genetic evolution during the disease progression and therapy. Compared to ctDNA, CTCs have a longer half-life in blood, and the analysis of viable cells could provide information about protein expression, such as PD-L1 or ER, which is not possible with ctDNA. Also, since CTCs contain intact genomic material from tumors, their analysis can reveal additional information about the biology of cancer and metastasis that is not possible to obtain from ctDNA.

This report segments market by type of cancer and corresponding regional market. For segmentation by type of analyte and type of application, see Kalorama's larger study on Liquid Biopsy Markets.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • INTRODUCTION
  • LIQUID BIOPSY TECHNOLOGIES
  • INDUSTRY STRUCTURE
  • LIQUID BIOPSY MARKET REVENUES AND FORECAST

CHAPTER TWO: LIQUID BIOPSY TECHNOLOGIES

  • INTRODUCTION
    • Table 2-1 Comparison of Tissue and Liquid Biopsy
  • CURRENT MAJOR LIQUID BIOPSY TECHNOLOGIES
    • Table 2-2 Advantages and Limitations of Major Liquid Biopsy Technologies
  • CIRCULATING FREE DNA
  • ADVANTAGES AND LIMITATIONS OF CTDNA IN LIQUID BIOPSY
  • CURRENT CTDNA-BASED LIQUID BIOPSY TESTS
    • Table 2-3 Selected Market-Available ctDNA-based Liquid Biopsy Tests, 2017
  • Adaptive Biotechnologies
  • Biodesix
  • Epigenomics
  • Foundation Medicine
  • Genomic Health
  • Guardant Health
  • Myriad Genetics
  • Pathway Genomics
  • Personal Genome Diagnostics
  • QIAGEN
  • Roche Diagnostics
  • Sysmex-Inostics
  • Trovagene
  • CIRCULATING TUMOR CELLS (CTCS) LIQUID BIOPSY
  • CHALLENGES IN THE DEVELOPMENT OF CTCS-BASED LIQUID BIOPSY TESTS
  • CTCS-BASED LIQUID BIOPSY TESTS
    • Table 2-4 Selected Market-Available CTCs-based Liquid Biopsy Tests, 2017
  • Biocept
  • Cynvenio Biosystems
  • Epic Sciences
  • GILUPI
  • Menarini-Silicon Biosystems
  • QIAGEN
  • EXTRACELLULAR VESICLES AND OTHER LIQUID BIOPSY
  • INTRODUCTION
  • LIQUID BIOPSY TESTS BASED ON EXTRACELLULAR VESICLES
    • Table 5-1 Selected Liquid Biopsy Tests Based on Extracellular Vesicles/Other Analytes, 2017
  • Biodesix
  • Exosome Diagnostics
  • Gensignia
  • Hologic
  • MDxHealth
  • OncoCyte
  • QIAGEN
  • Vermillion
  • VolitionRx

CHAPTER THREE: LIQUID BIOPSY INDUSTRY ANALYSIS

  • INTRODUCTION
  • TIERS OF COMPETITION
    • Table 3-1 Selected Competitors in the Liquid Biopsy Market, 2017
  • COMPETITIVE FACTORS
  • SIGNIFICANT MARKET TRENDS
    • Table 3-2 Significant Trends in the Liquid Biopsy Diagnostics and Monitoring Tests Market, 2017
  • Personalized Medicine to Spur Use of Liquid Biopsy Tests in Clinical Practice
  • Increasing Global Incidence of Cancer and Life Expectancy to Increase Testing Volumes
  • New Liquid Biopsy Product Launches to Augment Market Revenues
  • Decreasing Cost of Genetic Testing to Increase Utilization of Liquid Biopsy Tests
  • Regulatory Hurdles to Limit Market Growth
  • Limitations in Third-party Payer Coverage to Restrict Test Utilization and Market Growth
  • Insufficient Demonstrated Clinical Utility to Slow Adoption by Oncologists
  • Challenges in the Integration of Liquid Biopsy Tests in Clinical Practice to Limit Market Growth

CHAPTER FOUR: CANCER LIQUID BIOPSY MARKET ANALYSIS

  • OVERALL LIQUID MARKET SNAPSHOT
    • Table 4-1 Global Liquid Biopsy Market by Type of Cancer ($ millions), 2015-2021
    • Figure 4-1 Global Liquid Biopsy Market by Type of Cancer ($ millions), 2015-2021
  • TOP TEN COMPANIES IN THE LIQUID BIOPSY MARKET
    • Table 4-2 Top Ten Companies in the Liquid Biopsy Market
  • BREAST CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-3 Breast Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • COLORECTAL CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-4: Colorectal Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • LUNG CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-5: Lung Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • OVARIAN CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-6: Ovarian Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • PROSTATE CANCER
  • Market Snapshot
  • Revenue Forecast
    • Table 4-7: Prostate Cancer Liquid Biopsy Market - by Region (US, EUR, ASIA, ROW)
  • OTHER CANCERS
  • Market Snapshot
  • Revenue Forecast
    • Table 4-8: Other Cancer Liquid Biopsy Market
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.